MoneyWorks4Me

Check Before You Invest : Shukra Medtech Ltd

BSE: 524632 NSE: SHUKRAPHAR ISIN: INE551C01044
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Shukra Medtech Ltd belong to?
Shukra Medtech Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Shukra Medtech Ltd a good quality company?
Shukra Medtech Ltd is a weak quality company, based on a inconsistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

Q.3 Is Shukra Medtech Ltd undervalued or overvalued?
Shukra Medtech Ltd appears Overvalued, as its key valuation ratios are higher than their past averages.

Based on the industry it operates in, the relevant valuation ratios include one of the following, P/E, P/BV, P/Sales, EV/EBITDA or a combination of two or more.

Valuation Ratios Current 0-year
Historic Median
Price to Earnings - -
Price to Book - -
Price to Sales - -
EV to EBITDA - -
Q.4 Is Shukra Medtech Ltd a good buy now?
Shukra Medtech Ltd is a good buy now, based on strong price trend analysis suggesting prices may rise. However, you need to check its quality and valuation before making a decision

Performance Analysis

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

C: How much debt does the business have and is it at a sustainable level?

Q.1 Debt to Equity ratio of Shukra Medtech Ltd?
Shukra Medtech Ltd Debt-to-Equity ratio is 0.00, which is lower the industry average of 0.14, indicating lower debt levels in the industry.

Ownership & governance

D: Promoter shareholding and pledge status of Shukra Medtech Ltd?

Q.1 Promoter shareholding and pledge status of Shukra Medtech Ltd?
Promoters hold 50.96% of the Shukra Medtech Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

E: How does Shukra Medtech Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Shukra Medtech Ltd vs industry peers?
Shukra Medtech Ltd revenue CAGR is 0.00%, compared to the industry median CAGR of %, indicating stable growth and maintaining its market share.
Profit Metrics
Current Level 0-year
Industry Median
Revenue Growth (%) - -
Gross Profit Growth (%) 0 -
Operating Profit Growth (%) 0 -
Net Profit Growth (%) 0 -
Operating Efficiency
Current Level 0-year
Industry Median
Asset Turnover (x) - -
ROE (%) 7.98 -
ROCE (%) 154.44 -
Cash Conversion Cycle (days) - -

Valuation & price assessment

Q.1 Stock return of Shukra Medtech Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 70.1% based on the current price.
9Y 5Y 3Y 1Y
Share Price
CAGR
70.1% 191.1% 188.6% 90.5%
Q.2 Valuation ratios of Shukra Medtech Ltd vs historical?
The current P/E ratio of 0 is in line with than its historical median of , indicating that the stock is trading near its historical average valuation.
Q.3 How do the current valuation ratios compare with 0-year historical median and industry numbers?
Valuation Ratios Current 0-year
Historic Median
0-year
Industry Median
Price to Earnings - - 29.21
Price to Book - - 2.86
Price to Sales - - 2.70
EV to EBITDA - - 15.83

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: